Attomarker

Executive Summary

Attomarker is a UK-based precision diagnostics company that has developed a rapid, lab-quality multiplex blood testing platform capable of simultaneously quantifying multiple biomarkers from a single sample within minutes. The company’s initial commercial product, a UKCA-authorized COVID-19 antibody test, validates the platform’s ability to deliver accurate, point-of-care results. By focusing on immunology and infectious diseases, Attomarker addresses a growing demand for decentralized, rapid diagnostics that can reduce turnaround times and healthcare costs. The platform’s versatility allows it to be adapted for a wide range of applications, including autoimmune disease monitoring, allergy testing, and infectious disease panels beyond COVID-19. With its headquarters in Exeter, United Kingdom, Attomarker is well-positioned to expand its product portfolio and enter new markets, leveraging its core technology to capture share in the global rapid diagnostics market. The company’s near-term growth hinges on expanding its test menu and securing regulatory approvals in key regions. Attomarker plans to launch additional multiplex panels targeting Lyme disease, respiratory infections, and autoimmune conditions, which could unlock significant revenue opportunities. Additionally, the company is pursuing CE marking under the new IVDR and exploring FDA clearance for its platform, which would open the large US market. Strategic partnerships with major diagnostics distributors or healthcare providers could accelerate commercialization and provide validation. Given its existing commercial product and scalable platform, Attomarker is poised for growth, but execution risk remains around regulatory timelines and competitive dynamics.

Upcoming Catalysts (preview)

• Q4 2026Launch of a new multiplex panel (e.g., Lyme disease or autoimmune panel) in Europe70% success
• Q1 2027CE marking approval under IVDR for the core platform60% success
• H2 2026Strategic partnership with a major diagnostics distributor for US market entry50% success